The content on this site is intended for healthcare professionals only
Dr Jyoti Bajpai speaks to ecancer about her open-label phase III OLAnzaPiNE trial evaluating low-dose compared to standard-dose olanzapine with triple antiemetic therapy for prevention of highly emetogenic chemotherapy-induced nausea and vomiting in solid tumours.
Dr Bajpai initially talks about the objective and the design of the trial.
The study found that low-dose olanzapine is non-inferior to standard dose in anti-emetic efficacy and results in lower daytime somnolence among patients receiving highly emetogenic chemotherapy and could be a standard of care.
Sacituzumab govitecan improves PFS in first-line metastatic TNBC patients unable to receive PD-(L)1 inhibitors
Breast cancer survivorship
Burden and trends of breast cancer worldwide: Opportunities for prevention?
Key insights from lung cancer research at ASCO 2025
ELCC 2025: Latest in EGFR positive NSCLC
CDK4/6 inhibitors and endocrine therapy in elderly female patients with advanced hormone receptor positive HER-2 negative BC
ESMO and WCLC: Latest developments in EGFR mutated NSCLC
Advancements in paediatric Acute lymphoblastic leukemia management
Enhancing head and neck oncology: Key insights from the conference
